Axa XL extends cyber cover to internal GenAI risks

artificial intelligence

Axa XL has extended its cyber insurance coverage to emerging generative artificial intelligence risks, but risks associated with popular GenAI chatbots such as ChatGPT and Microsoft Copilot remain out of scope.

The new coverage is available by an endorsement to the insurer’s cyber policies globally and is designed to affirm cover for risks that policies were previously unclear or silent on associated with

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@postonline.co.uk or view our subscription options here: http://subscriptions.postonline.co.uk/subscribe

You are currently unable to copy this content. Please contact info@postonline.co.uk to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Insurance Post? View our subscription options

Register

Want to know what’s included in our free registration? Click here

Already have an account? Sign in here

This address will be used to create your account

Insurers shift to being net zero accelerators

How insurers are helping companies decarbonise sooner rather than later is examined in the first of two special Insurance Post Podcasts, to coincide with the 2024 United Nations Climate Change Conference, more commonly known as COP29.

How to enable the renewable energy transition

Jack O’Sullivan, senior underwriter at Rokstone in the energy and power division, argues renewable energy will always attract capacity, but insurers, brokers, and developers need to act more collaboratively to ensure more quality, robust projects are being built that can withstand the perils they are exposed to.

Most read articles loading...

You need to sign in to use this feature. If you don’t have an Insurance Post account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here